Review

Cannabinoids as novel anti-inflammatory drugs

† Author for correspondence

Department of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine Columbia, SC 29208, USA.

Search for more papers by this author

Email the corresponding author at pnagark@uscmed.sc.edu

Rupal Pandey^*

Department of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine Columbia, SC 29208, USA.

^*Both authors contributed equally to this review

Search for more papers by this author

Email the corresponding author at pnagark@uscmed.sc.edu

Sadiye Amcaoglu Rieder^*

Department of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine Columbia, SC 29208, USA.

^*Both authors contributed equally to this review

Search for more papers by this author

Email the corresponding author at pnagark@uscmed.sc.edu

Venkatesh L Hegde

Department of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine Columbia, SC 29208, USA.

Search for more papers by this author

Email the corresponding author at pnagark@uscmed.sc.edu

Mitzi Nagarkatti

Department of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine Columbia, SC 29208, USA.

Search for more papers by this author

Email the corresponding author at pnagark@uscmed.sc.edu

Published Online:21 Oct 2009https://doi.org/10.4155/fmc.09.93

Abstract

Cannabinoids are a group of compounds that mediate their effects through cannabinoid receptors. The discovery of Δ⁹-tetrahydrocannabinol (THC) as the major psychoactive principle in marijuana, as well as the identification of cannabinoid receptors and their endogenous ligands, has led to a significant growth in research aimed at understanding the physiological functions of cannabinoids. Cannabinoid receptors include CB1, which is predominantly expressed in the brain, and CB2, which is primarily found on the cells of the immune system. The fact that both CB1 and CB2 receptors have been found on immune cells suggests that cannabinoids play an important role in the regulation of the immune system. Recent studies demonstrated that administration of THC into mice triggered marked apoptosis in T cells and dendritic cells, resulting in immunosuppression. In addition, several studies showed that cannabinoids downregulate cytokine and chemokine production and, in some models, upregulate T-regulatory cells (Tregs) as a mechanism to suppress inflammatory responses. The endocannabinoid system is also involved in immunoregulation. For example, administration of endocannabinoids or use of inhibitors of enzymes that break down the endocannabinoids, led to immunosuppression and recovery from immune-mediated injury to organs such as the liver. Manipulation of endocannabinoids and/or use of exogenous cannabinoids in vivo can constitute a potent treatment modality against inflammatory disorders. This review will focus on the potential use of cannabinoids as a new class of anti-inflammatory agents against a number of inflammatory and autoimmune diseases that are primarily triggered by activated T cells or other cellular immune components.

Bibliography

1 Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer3,745–755 (2003).Crossref, Medline, CAS, Google Scholar
2 Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J. Clin.52,72–91 (2002).Crossref, Medline, Google Scholar
3 Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs22,291–324 (2008).Crossref, Medline, Google Scholar
4 Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ323,16–21 (2001).Crossref, Medline, CAS, Google Scholar
5 Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J. Neuroimmunol.166,3–18 (2005).Crossref, Medline, CAS, Google Scholar
6 Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol.46,101–122 (2006).Crossref, Medline, CAS, Google Scholar
7 Stefano GB, Liu Y, Goligorsky MS. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem.271,19238–19242 (1996).Crossref, Medline, CAS, Google Scholar
8 Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science258,1946–1949 (1992).Crossref, Medline, CAS, Google Scholar
9 Mechoulam R, Ben-Shabat S, Hanus L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol.50,83–90 (1995).Crossref, Medline, CAS, Google Scholar
10 Sugiura T, Kondo S, Sukagawa A et al. 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun.215,89–97 (1995).Crossref, Medline, CAS, Google Scholar
11 Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature384,83–87 (1996).Crossref, Medline, CAS, Google Scholar
12 Kaczocha M, Glaser ST, Deutsch DG. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl Acad. Sci. USA106,6375–6380 (2009).Crossref, Medline, CAS, Google Scholar
13 Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcoholism40,2–14 (2005).Crossref, Medline, CAS, Google Scholar
14 Hengartner MO. The biochemistry of apoptosis. Nature407,770–776 (2000).Crossref, Medline, CAS, Google Scholar
15 Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer2,277–288 (2002).Crossref, Medline, CAS, Google Scholar
16 Zhu W, Friedman H, Klein TW. Δ9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J. Pharmacol. Exp. Ther.286,1103–1109 (1998).Medline, CAS, Google Scholar
17 McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. D(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther.302,451–465 (2002).Crossref, Medline, CAS, Google Scholar
18 Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-κB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol.173,2373–2382 (2004).Crossref, Medline, CAS, Google Scholar
19 Lu T, Newton C, Perkins I, Friedman H, Klein TW. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J. Pharmacol. Exp. Ther.319,269–276 (2006).Crossref, Medline, CAS, Google Scholar
20 Lee CY, Wey SP, Liao MH et al. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int. Immunopharmacol.8,732–740 (2008).Crossref, Medline, CAS, Google Scholar
21 Bidinger B, Torres R, Rossetti RG et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin. Immunol.108,95–102 (2003).Crossref, Medline, CAS, Google Scholar
22 Lombard C, Nagarkatti M, Nagarkatti P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin. Immunol.122,259–270 (2007).Crossref, Medline, CAS, Google Scholar
23 Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res.67,829–836 (2002).Crossref, Medline, CAS, Google Scholar
24 Croxford JL, Pryce G, Jackson SJ et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J. Neuroimmunol.193,120–129 (2008).Crossref, Medline, CAS, Google Scholar
25 Klein TW, Newton CA, Nakachi N, Friedman H. Δ9-tetrahydrocannabinol treatment suppresses immunity and early IFN-γ, IL-12, and IL-12 receptor β 2 responses to Legionella pneumophila infection. J. Immunol.164,6461–6466 (2000).Crossref, Medline, CAS, Google Scholar
26 Srivastava MD, Srivastava BI, Brouhard B. Δ9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology40,179–185 (1998).Crossref, Medline, CAS, Google Scholar
27 Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, Casellas P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J. Biol. Chem.275,15621–15628 (2000).Crossref, Medline, CAS, Google Scholar
28 Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia29,58–69 (2000).Crossref, Medline, CAS, Google Scholar
29 Smith SR, Terminelli C, Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther.293,136–150 (2000).Medline, CAS, Google Scholar
30 Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res. Ther.8(Suppl. 2),S5 (2006).Crossref, Medline, Google Scholar
31 Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum.41,163–170 (1998).Crossref, Medline, CAS, Google Scholar
32 Parker J, Atez F, Rossetti RG, Skulas A, Patel R, Zurier RB. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol. Int.28,631–635 (2008).Crossref, Medline, CAS, Google Scholar
33 Rajesh M, Pan H, Mukhopadhyay P et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukoc. Biol.82,1382–1389 (2007).Crossref, Medline, CAS, Google Scholar
34 Selvi E, Lorenzini S, Garcia-Gonzalez E et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol.26,574–581 (2008).Medline, CAS, Google Scholar
35 Valk P, Verbakel S, Vankan Y et al. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood90,1448–1457 (1997).Crossref, Medline, CAS, Google Scholar
36 Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Mol. Pharmacol.70,101–111 (2006).Crossref, Medline, CAS, Google Scholar
37 Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J. Biochem.135,517–524 (2004).Crossref, Medline, CAS, Google Scholar
38 Mestre L, Correa F, Arevalo-Martin A et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem.92,1327–1339 (2005).Crossref, Medline, CAS, Google Scholar
39 Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agro A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J. Immunol.166,7183–7189 (2001).Crossref, Medline, CAS, Google Scholar
40 Fischer-Stenger K, Dove Pettit DA, Cabral GA. Δ9-tetrahydrocannabinol inhibition of tumor necrosis factor-α: suppression of post-translational events. J. Pharmacol. Exp. Ther.267,1558–1565 (1993).Medline, CAS, Google Scholar
41 Zhu W, Newton C, Dka Y, Friedman H, Klein TW. Δ9-tetrahydrocannabinol enhances the secretion of interleukin 1 from endotoxin-stimulated macrophages. J. Pharmacol. Exp. Ther.270,1334–1339 (1994).Medline, CAS, Google Scholar
42 Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol.65,239–248 (2009).Crossref, Medline, CAS, Google Scholar
43 Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol. Ther.95,165–174 (2002).Crossref, Medline, CAS, Google Scholar
44 Arevalo-Martin A, Garcia-Ovejero D, Gomez O et al. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br. J. Pharmacol.153,216–225 (2008).Crossref, Medline, CAS, Google Scholar
45 Centonze D, Bari M, Rossi S et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain130,2543–2553 (2007).Crossref, Medline, Google Scholar
46 Ghosh S, Preet A, Groopman JE, Ganju RK. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol.43,2169–2179 (2006).Crossref, Medline, CAS, Google Scholar
47 Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia36,220–234 (2001).Crossref, Medline, CAS, Google Scholar
48 Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int.57,115–120 (2008).Crossref, Medline, CAS, Google Scholar
49 Frisullo G, Nociti V, Iorio R et al. IL17 and IFNγ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine44,22–25 (2008).Crossref, Medline, CAS, Google Scholar
50 Sanchez AJ, Gonzalez-Perez P, Galve-Roperh I, Garcia-Merino A. R-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4 -benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem. Pharmacol.72,1697–1706 (2006).Crossref, Medline, CAS, Google Scholar
51 Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci.23,2511–2516 (2003).Crossref, Medline, CAS, Google Scholar
52 Mestre L, Docagne F, Correa F et al. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell Neurosci.40,258–266 (2009).Crossref, Medline, CAS, Google Scholar
53 Ehrhart J, Obregon D, Mori T et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation2,29 (2005).Crossref, Medline, Google Scholar
54 Correa F, Docagne F, Mestre L et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem. Pharmacol.77,86–100 (2009).Crossref, Medline, CAS, Google Scholar
55 Palazuelos J, Davoust N, Julien B et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem.283,13320–13329 (2008).Crossref, Medline, CAS, Google Scholar
56 Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK. Synthetic cannabinoid WIN55,212–212 inhibits generation of inflammatory mediators by IL-1β-stimulated human astrocytes. Glia49,211–219 (2005).Crossref, Medline, Google Scholar
57 Molina-Holgado F, Molina-Holgado E, Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler’s murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett.433,139–142 (1998).Crossref, Medline, CAS, Google Scholar
58 Wood JD, Alpers DH, Andrews PL. Fundamentals of neurogastroenterology. Gut45(Suppl. 2.),II6–II16 (1999).Crossref, Medline, Google Scholar
59 Massa F, Marsicano G, Hermann H et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest.113,1202–1209 (2004).Crossref, Medline, CAS, Google Scholar
60 Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut48,859–867 (2001).Crossref, Medline, CAS, Google Scholar
61 Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology98,694–702 (1990).Crossref, Medline, CAS, Google Scholar
62 Yamada Y, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology102,1524–1534 (1992).Crossref, Medline, CAS, Google Scholar
63 Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med.182,1281–1290 (1995).Crossref, Medline, CAS, Google Scholar
64 Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am. J. Physiol. Gastrointest. Liver Physiol.291,G364–G371 (2006).Crossref, Medline, CAS, Google Scholar
65 Izzo AA, Fezza F, Capasso R et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol.134,563–570 (2001).Crossref, Medline, CAS, Google Scholar
66 Cravatt BF, Demarest K, Patricelli MP et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA98,9371–9376 (2001).Crossref, Medline, CAS, Google Scholar
67 Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids66,377–391 (2002).Crossref, Medline, CAS, Google Scholar
68 Biecker E, Sagesser H, Reichen J. Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase 3-deficient mice. Eur. J. Clin. Invest.34,283–289 (2004).Crossref, Medline, CAS, Google Scholar
69 Julien B, Grenard P, Teixeira-Clerc F et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology128,742–755 (2005).Crossref, Medline, CAS, Google Scholar
70 Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest.115,1298–1305 (2005).Crossref, Medline, CAS, Google Scholar
71 Schwabe RF, Siegmund SV. Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C. Hepatology42,975–977 (2005).Crossref, Medline, Google Scholar
72 Teixeira-Clerc F, Julien B, Grenard P et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med.12,671–676 (2006).Crossref, Medline, CAS, Google Scholar
73 Batkai S, Jarai Z, Wagner JA et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med.7,827–832 (2001).Crossref, Medline, CAS, Google Scholar
74 Batkai S, Osei-Hyiaman D, Pan H et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J.21,1788–1800 (2007).Crossref, Medline, CAS, Google Scholar
75 Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology46,122–129 (2007).Crossref, Medline, CAS, Google Scholar
76 Siegmund SV, Qian T, de Minicis S et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J.21,2798–2806 (2007).Crossref, Medline, CAS, Google Scholar
77 Hezode C, Roudot-Thoraval F, Nguyen S et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology42,63–71 (2005).Crossref, Medline, CAS, Google Scholar
78 Avraham Y, Israeli E, Gabbay E et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol. Dis.21,237–245 (2006).Crossref, Medline, CAS, Google Scholar
79 Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol.74,20–33 (2008).Crossref, Medline, CAS, Google Scholar
80 Hurlimann D, Enseleit F, Ruschitzka F. Rheumatoid arthritis, inflammation, and atherosclerosis. Herz29,760–768 (2004).Crossref, Medline, Google Scholar
81 Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol.23,37–48 (2009).Crossref, Medline, CAS, Google Scholar
82 Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1β production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem. Pharmacol.65,649–655 (2003).Crossref, Medline, CAS, Google Scholar
83 George KL, Saltman LH, Stein GS, Lian JB, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J. Cell Physiol.214,714–720 (2008).Crossref, Medline, CAS, Google Scholar
84 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet357,539–545 (2001).Crossref, Medline, CAS, Google Scholar
85 Malfait AM, Gallily R, Sumariwalla PF et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA97,9561–9566 (2000).Crossref, Medline, CAS, Google Scholar
86 Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum.50,985–998 (2004).Crossref, Medline, CAS, Google Scholar
87 Mamytbekova A, Rezabek K, Kacerovska H, Grimova J, Svobodova J. Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors. Neoplasma33,417–421 (1986).Medline, CAS, Google Scholar
88 Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res.68,339–342 (2008).Crossref, Medline, CAS, Google Scholar
89 Carracedo A, Gironella M, Lorente M et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res.66,6748–6755 (2006).Crossref, Medline, CAS, Google Scholar
90 Casanova ML, Blazquez C, Martinez-Palacio J et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest.111,43–50 (2003).Crossref, Medline, CAS, Google Scholar
91 Galve-Roperh I, Sanchez C, Cortes ML et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med.6,313–319 (2000).Crossref, Medline, CAS, Google Scholar
92 Sanchez C, de Ceballos ML, Gomez del Pulgar T et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res.61,5784–5789 (2001).Medline, CAS, Google Scholar
93 Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res.65,1635–1641 (2005).Crossref, Medline, CAS, Google Scholar
94 Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Guzman M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology47,315–323 (2004).Crossref, Medline, CAS, Google Scholar
95 Lombard C, Nagarkatti M, Nagarkatti PS. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Δ9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk. Res.29,915–922 (2005).Crossref, Medline, CAS, Google Scholar
96 Jia W, Hegde VL, Singh NP et al. Δ9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol. Cancer Res.4,549–562 (2006).Crossref, Medline, CAS, Google Scholar
97 McKallip RJ, Lombard C, Fisher M et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood100,627–634 (2002).Crossref, Medline, CAS, Google Scholar
98 Ligresti A, Bisogno T, Matias I et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology125,677–687 (2003).Crossref, Medline, CAS, Google Scholar
99 Cianchi F, Papucci L, Schiavone N et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated ceramide de novo synthesis in colon cancer cells. Clin. Cancer Res.14,7691–7700 (2008).Crossref, Medline, CAS, Google Scholar
100 Bifulco M, Laezza C, Valenti M et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J.18,1606–1608 (2004).Crossref, Medline, CAS, Google Scholar
101 De Lago E, Gustafsson SB, Fernandez-Ruiz J et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J. Neurochem.99,677–688 (2006).Crossref, Medline, CAS, Google Scholar
102 Endsley MP, Aggarwal N, Isbell MA et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int. J. Cancer121,984–991 (2007).Crossref, Medline, CAS, Google Scholar
103 Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem. Biophys. Res. Commun.332,1028–1033 (2005).Crossref, Medline, CAS, Google Scholar
104 Contassot E, Tenan M, Schnuriger V, Pelte MF, Dietrich PY. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol. Oncol.93,182–188 (2004).Crossref, Medline, CAS, Google Scholar
105 Contassot E, Wilmotte R, Tenan M et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J. Neuropathol. Exp. Neurol.63,956–963 (2004).Crossref, Medline, CAS, Google Scholar
106 DeMorrow S, Glaser S, Francis H et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J. Biol. Chem.282,13098–13113 (2007).Crossref, Medline, CAS, Google Scholar
107 Bifulco M, Laezza C, Portella G et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J.15,2745–2747 (2001).Crossref, Medline, CAS, Google Scholar
108 Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res.66,6615–6621 (2006).Crossref, Medline, CAS, Google Scholar
109 Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res.62,4398–4405 (2002).Medline, CAS, Google Scholar
110 Islam TC, Asplund AC, Lindvall JM et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of cyclin D1 in mantle cell lymphoma. Leukemia17,1880–1890 (2003).Crossref, Medline, CAS, Google Scholar
111 Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol.17,255–281 (1999).Crossref, Medline, CAS, Google Scholar
112 Anderson GP, Coyle AJ. TH2 and ‘TH2-like’ cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol. Sci.15,324–332 (1994).Crossref, Medline, CAS, Google Scholar
113 Jan TR, Farraj AK, Harkema JR, Kaminski NE. Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol. Appl. Pharmacol.188,24–35 (2003).Crossref, Medline, CAS, Google Scholar
114 Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of aerosolized Δ9-tetrahydrocannabinol in healthy and asthmatic subjects. Am. Rev. Respir. Dis.115,57–65 (1977).Medline, CAS, Google Scholar
115 Abboud RT, Sanders HD. Effect of oral administration of D-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest70,480–485 (1976).Crossref, Medline, CAS, Google Scholar
116 Hartley JP, Nogrady SG, Seaton A. Bronchodilator effect of D1-tetrahydrocannabinol. Br. J. Clin. Pharmacol.5,523–525 (1978).Crossref, Medline, CAS, Google Scholar
117 Calignano A, Katona I, Desarnaud F et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature408,96–101 (2000).Crossref, Medline, CAS, Google Scholar
118 Rajesh M, Mukhopadhyay P, Batkai S et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am. J. Physiol. Heart Circ. Physiol.293,H610–H619 (2007).Crossref, Medline, CAS, Google Scholar
119 Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-α-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol.153,347–357 (2008).Crossref, Medline, CAS, Google Scholar
120 de Kozak Y, Sakai J, Thillaye B, Faure JP. S antigen-induced experimental autoimmune uveo-retinitis in rats. Curr. Eye Res.1,327–337 (1981).Crossref, Medline, CAS, Google Scholar
121 Xu H, Cheng CL, Chen M et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J. Leukoc. Biol.82,532–541 (2007).Crossref, Medline, CAS, Google Scholar
122 Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol.145,441–448 (2005).Crossref, Medline, CAS, Google Scholar
123 Broderick CA, Smith AJ, Balaggan KS et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol. Ther.12,369–373 (2005).Crossref, Medline, CAS, Google Scholar
124 De Kozak Y, Thillaye-Goldenberg B, Naud MC, Da Costa AV, Auriault C, Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin. Exp. Immunol.130,212–223 (2002).Crossref, Medline, CAS, Google Scholar
125 Mandrup-Poulsen T. β cell death and protection. Ann. NY Acad. Sci.1005,32–42 (2003).Crossref, Medline, Google Scholar
126 Li X, Kaminski NE, Fischer LJ. Examination of the immunosuppressive effect of Δ9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int. Immunopharmacol.1,699–712 (2001).Crossref, Medline, CAS, Google Scholar
127 Weiss L, Zeira M, Reich S et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity39,143–151 (2006).Crossref, Medline, CAS, Google Scholar
128 Weiss L, Zeira M, Reich S et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology54,244–249 (2008).Crossref, Medline, CAS, Google Scholar
129 El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood–retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am. J. Pathol.168,235–244 (2006).Crossref, Medline, CAS, Google Scholar
130 Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci. Lett.368,82–86 (2004).Crossref, Medline, CAS, Google Scholar

- Cited By
  - Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors
    Bioorganic & Medicinal Chemistry, Vol. 28, No. 1
  - Cannabinoids and the Microbiota–Gut–Brain Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders
    24 December 2019 | Alcoholism: Clinical and Experimental Research, Vol. 29
  - The effect of high maternal linoleic acid on endocannabinoid signalling in rodent hearts
    9 December 2019 | Journal of Developmental Origins of Health and Disease, Vol. 52
  - Acute and short-term administrations of delta-9-tetrahydrocannabinol modulate major gut metabolomic regulatory pathways in C57BL/6 mice
    19 July 2019 | Scientific Reports, Vol. 9, No. 1
  - Cannabidiol Regulates Gene Expression in Encephalitogenic T cells Using Histone Methylation and noncoding RNA during Experimental Autoimmune Encephalomyelitis
    31 October 2019 | Scientific Reports, Vol. 9, No. 1
  - Total and differential white blood cell count in cannabis users: results from the cross-sectional National Health and Nutrition Examination Survey, 2005–2016
    9 July 2019 | Journal of Cannabis Research, Vol. 1, No. 1
  - Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients
    20 November 2019 | Brain Sciences, Vol. 9, No. 12
  - Pulmonary effects of inhaled cannabis smoke
    12 July 2019 | The American Journal of Drug and Alcohol Abuse, Vol. 45, No. 6
  - Cannabidiol differentially regulates basal and LPS-induced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts
    Toxicology and Applied Pharmacology, Vol. 382
  - Cannabis Use and Markers of Systemic Inflammation: The Coronary Artery Risk Development in Young Adults Study
    The American Journal of Medicine, Vol. 132, No. 11
  - Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome
    Brain, Behavior, and Immunity, Vol. 82
  - Cannabis and Cannabinoids on Treatment of Inflammation: A Patent Review
    Recent Patents on Biotechnology, Vol. 13, No. 4
  - New and emerging treatments for vaso-occlusive pain in sickle cell disease
    6 August 2019 | Expert Review of Hematology, Vol. 12, No. 10
  - Hierarchical control systems for the regulation of physiological homeostasis and affect: Can their interactions modulate mood and anhedonia?
    Neuroscience & Biobehavioral Reviews, Vol. 105
  - Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation
    23 September 2019 | Journal of Geriatric Psychiatry and Neurology, Vol. 25
  - 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer’s Disease: Analyses from a Clinical Trial with Nabilone
    Journal of Alzheimer's Disease, Vol. 71, No. 1
  - 5-Chlorobenzofuran-2-carboxamides: From allosteric CB1 modulators to potential apoptotic antitumor agents
    European Journal of Medicinal Chemistry, Vol. 177
  - Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways
    21 August 2019 | Frontiers in Immunology, Vol. 10
  - Cannabinoid CB2 Receptor Functional Variation (Q63R) Is Associated with Multiple Sclerosis in Iranian Subjects
    13 August 2019 | Journal of Molecular Neuroscience, Vol. 44
  - Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats
    9 August 2019 | Frontiers in Cellular Neuroscience, Vol. 13
  - Diabetes Canada Position Statement on Recreational Cannabis Use in Adults and Adolescents With Type 1 and Type 2 Diabetes
    Canadian Journal of Diabetes, Vol. 43, No. 6
  - Cannabinoids and inflammation
    AIDS
  - Allostatic load and the cannabinoid system: implications for the treatment of physiological abnormalities in post-traumatic stress disorder (PTSD)
    15 July 2019 | CNS Spectrums, Vol. 13
  - From Cannabinoids and Neurosteroids to Statins and the Ketogenic Diet: New Therapeutic Avenues in Rett Syndrome?
    2 July 2019 | Frontiers in Neuroscience, Vol. 13
  - Impact of habitual marijuana and tobacco smoke on severity of chronic rhinosinusitis
    American Journal of Otolaryngology, Vol. 40, No. 4
  - Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice
    14 May 2019 | Journal of Psychopharmacology, Vol. 33, No. 7
  - Associations of first trimester co-use of tobacco and Cannabis with prenatal immune response and psychosocial well-being
    Neurotoxicology and Teratology, Vol. 73
  - Cannabinoid Attenuation of Intestinal Inflammation in Chronic SIV-Infected Rhesus Macaques Involves T Cell Modulation and Differential Expression of Micro-RNAs and Pro-inflammatory Genes
    30 April 2019 | Frontiers in Immunology, Vol. 10
  - Lung alveolar tissue destruction and protein citrullination in diesel exhaust‐exposed mouse lungs
    2 April 2019 | Basic & Clinical Pharmacology & Toxicology, Vol. 163
  - Cannabis sativa L. Constituents and Their Role in Neuroinflammation
    Current Bioactive Compounds, Vol. 15, No. 2
  - miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia—Effect of cannabinoids
    11 February 2019 | PLOS ONE, Vol. 14, No. 2
  - Cannabinoid exposure during pregnancy and its impact on immune function
    29 October 2018 | Cellular and Molecular Life Sciences, Vol. 76, No. 4
  - Gene Expression of ABHD6, a Key Factor in the Endocannabinoid System, Can Be Modulated by Female Hormones in Human Immune Cells
    13 July 2018 | Biochemical Genetics, Vol. 57, No. 1
  - Reduced Risk of Alcohol-Induced Pancreatitis With Cannabis Use
    20 December 2018 | Alcoholism: Clinical and Experimental Research, Vol. 43, No. 2
  - Neuroinflammation and Cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of Research Methods
    10 January 2019 | Frontiers in Neurology, Vol. 9
  - Neurologic and Psychiatric Effects of Cytokines and Targeted Biological Therapies
    30 June 2019
  - Cannabis Use Disorder During the Perinatal Period
    25 November 2018
  - Therapeutic implications of anti-inflammatory natural products in Alzheimer’s disease
  - Inflammatory mechanisms of abused drugs
  - Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma
    European Journal of Pharmacology, Vol. 843
  - Vitamin D Attenuates Myocardial Injury by Reduces ERK Phosphorylation Induced by I/R in Mice Model
    Current Chemical Genomics and Translational Medicine, Vol. 12, No. 1
  - Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer
    BioMed Research International, Vol. 2018
  - The Anti-Inflammatory Properties of Terpenoids from Cannabis
    Cannabis and Cannabinoid Research, Vol. 3, No. 1
  - Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort
    24 May 2018 | The Journal of Headache and Pain, Vol. 19, No. 1
  - Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation
    Hormone Molecular Biology and Clinical Investigation, Vol. 36, No. 2
  - Polyunsaturated fatty acids and endocannabinoids in health and disease
    7 July 2017 | Nutritional Neuroscience, Vol. 21, No. 10
  - The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders
    Biochemical Pharmacology, Vol. 157
  - Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB2 and GPR55 receptor activation. Possible involvement of CB2-GPR55 heteromers
    International Immunopharmacology, Vol. 64
  - Cannabidiol restores differentiation capacity of LPS exposed adipose tissue mesenchymal stromal cells
    Experimental Cell Research, Vol. 370, No. 2
  - Cannabidiol induced apoptosis in human monocytes through mitochondrial permeability transition pore-mediated ROS production
    Free Radical Biology and Medicine, Vol. 124
  - Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer's disease
    Life Sciences, Vol. 207
  - Cannabinoid receptor types 1 and 2 and peroxisome proliferator-activated receptor-α: distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis
    19 June 2018 | Veterinary Dermatology, Vol. 29, No. 4
  - Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
    27 August 2018 | Headache: The Journal of Head and Face Pain, Vol. 58, No. 7
  - Cannabinoids in the Management of Musculoskeletal Pain
    JBJS Reviews, Vol. 6, No. 5
  - Emerging Role of (Endo)Cannabinoids in Migraine
    24 April 2018 | Frontiers in Pharmacology, Vol. 9
  - The Aging of Iron Man
    12 March 2018 | Frontiers in Aging Neuroscience, Vol. 10
  - Neuroinflammation and sympathetic overactivity: Mechanisms and implications in hypertension
    Autonomic Neuroscience, Vol. 210
  - The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis
    6 February 2018 | PLOS ONE, Vol. 13, No. 2
  - Whole Organisms or Pure Compounds? Entourage Effect Versus Drug Specificity
    29 April 2018
  - Antiinflammatory Potential of Medicinal Plants: A Source for Therapeutic Secondary Metabolites
  - The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain
    31 August 2017 | Neuropsychopharmacology, Vol. 43, No. 1
  - Discovery of APD371: Identification of a Highly Potent and Selective CB 2 Agonist for the Treatment of Chronic Pain
    6 December 2017 | ACS Medicinal Chemistry Letters, Vol. 8, No. 12
  - Marijuana Use and Organ Transplantation: a Review and Implications for Clinical Practice
    27 October 2017 | Current Psychiatry Reports, Vol. 19, No. 11
  - Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon
    25 October 2017 | Clinical Science, Vol. 131, No. 21
  - New vistas on cannabis use disorder
    Neuropharmacology, Vol. 124
  - Asthma associated with the use of cocaine, heroin, and marijuana: A review of the evidence
    18 November 2016 | Journal of Asthma, Vol. 54, No. 7
  - Anti-inflammatory ω-3 endocannabinoid epoxides
    7 July 2017 | Proceedings of the National Academy of Sciences, Vol. 114, No. 30
  - Therapy implications of the role of interleukin-2 in cancer
    26 October 2016 | Expert Review of Clinical Immunology, Vol. 13, No. 5
  - Challenges to develop novel anti-inflammatory and analgesic drugs
    31 August 2016 | Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Vol. 9, No. 3
  - 2-Arachidonoylglycerol ameliorates inflammatory stress-induced insulin resistance in cardiomyocytes
    20 March 2017 | Journal of Biological Chemistry, Vol. 292, No. 17
  - Cannabinoid CB2 Receptor Mechanism of Cannabis sativa L.
    24 May 2017
  - Regulatory Role of Cannabinoids for Skin Barrier Functions and Cutaneous Inflammation
  - The Endocannabinoid System and Parkinson Disease
  - Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis
    Fitoterapia, Vol. 116
  - Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells
    3 June 2016 | Journal of Neuroinflammation, Vol. 13, No. 1
  - Host factors associated with serologic inflammatory markers assessed using multiplex assays
    Cytokine, Vol. 85
  - Docosahexaenoic acid attenuates in endocannabinoid synthesis in RAW 264.7 macrophages activated with benzo(a)pyrene and lipopolysaccharide
    Toxicology Letters, Vol. 258
  - Therapeutic Effects of Phytochemicals and Medicinal Herbs on Chemotherapy-Induced Peripheral Neuropathy
    20 September 2016 | Molecules, Vol. 21, No. 9
  - RNA-seq Analysis of δ9-Tetrahydrocannabinol-treated T Cells Reveals Altered Gene Expression Profiles That Regulate Immune Response and Cell Proliferation
    6 June 2016 | Journal of Biological Chemistry, Vol. 291, No. 30
  - Anti-Inflammatory and Osteoprotective Effects of Cannabinoid-2 Receptor Agonist HU-308 in a Rat Model of Lipopolysaccharide-Induced Periodontitis
    Journal of Periodontology, Vol. 87, No. 6
  - Hydroxytyrosol Inhibits Cannabinoid CB1 Receptor Gene Expression in 3T3-L1 Preadipocyte Cell Line
    22 October 2015 | Journal of Cellular Physiology, Vol. 231, No. 2
  - Marijuana Legalization: Impact on Physicians and Public Health
    Annual Review of Medicine, Vol. 67, No. 1
  - For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders
    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 64
  - HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells
    16 September 2015 | Chemical Biology & Drug Design, Vol. 87, No. 1
  - Elevated Levels of Endocannabinoids in Chronic Hepatitis C May Modulate Cellular Immune Response and Hepatic Stellate Cell Activation
    27 March 2015 | International Journal of Molecular Sciences, Vol. 16, No. 12
  - Vascular endothelial cell Toll-like receptor pathways in sepsis
    23 September 2015 | Innate Immunity, Vol. 21, No. 8
  - Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis
    1 October 2015 | PLOS Pathogens, Vol. 11, No. 10
  - Downstream effects of endocannabinoid on blood cells: implications for health and disease
    10 May 2015 | Cellular and Molecular Life Sciences, Vol. 72, No. 17
  - Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor
    2 June 2015 | Scientific Reports, Vol. 5, No. 1
  - Δ 9 -Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells
    1 June 2015 | Journal of Leukocyte Biology, Vol. 98, No. 3
  - Epigenetic Regulation of Immunological Alterations Following Prenatal Exposure to Marijuana Cannabinoids and its Long Term Consequences in Offspring
    25 January 2015 | Journal of Neuroimmune Pharmacology, Vol. 10, No. 2
  - Exposure to Δ9-Tetrahydrocannabinol Impairs the Differentiation of Human Monocyte-derived Dendritic Cells and their Capacity for T cell Activation
    23 January 2015 | Journal of Neuroimmune Pharmacology, Vol. 10, No. 2
  - Psychiatric Symptoms, Salivary Cortisol and Cytokine Levels in Young Marijuana Users
    15 April 2015 | Journal of Neuroimmune Pharmacology, Vol. 10, No. 2
  - Δ 9 Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells
    10 February 2015 | British Journal of Pharmacology, Vol. 172, No. 7
  - Central administration of GPR55 receptor agonist and antagonist modulates anxiety-related behaviors in rats
    11 March 2015 | Fundamental & Clinical Pharmacology, Vol. 29, No. 2
  - Δ 9 -Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8
    20 February 2015 | Journal of Leukocyte Biology, Vol. 97, No. 4
  - Cannabinoid CB2 receptor stimulation attenuates brain edema and neurological deficits in a germinal matrix hemorrhage rat model
    Brain Research, Vol. 1602
  - New Insights into Antimetastatic and Antiangiogenic Effects of Cannabinoids
  - Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells
    Journal of Neuroinflammation, Vol. 12, No. 1
  - Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1
    Biochemical Pharmacology, Vol. 92, No. 2
  - FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus
    Journal of Neuroimmunology, Vol. 276, No. 1-2
  - Δ 9 -Tetrahydrocannabinol-induced anti-inflammatory responses in adolescent mice switch to proinflammatory in adulthood
    17 April 2014 | Journal of Leukocyte Biology, Vol. 96, No. 4
  - Histone Modifications Are Associated with Δ 9 -Tetrahydrocannabinol-mediated Alterations in Antigen-specific T Cell Responses
    19 May 2014 | Journal of Biological Chemistry, Vol. 289, No. 27
  - Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats
    Journal of the Neurological Sciences, Vol. 342, No. 1-2
  - Adverse Health Effects of Marijuana Use
    New England Journal of Medicine, Vol. 370, No. 23
  - The Endocannabinoid/Endovanilloid N -Arachidonoyl Dopamine (NADA) and Synthetic Cannabinoid WIN55,212-2 Abate the Inflammatory Activation of Human Endothelial Cells
    18 March 2014 | Journal of Biological Chemistry, Vol. 289, No. 19
  - Simultaneous ultra-high performance liquid chromathograpy-electrospray ionization-quadrupole-time of flight mass spectrometry quantification of endogenous anandamide and related N-acylethanolamides in bio-matrices
    Journal of Chromatography B, Vol. 958
  - Vitreous biomarkers in diabetic retinopathy: A systematic review and meta-analysis
    Journal of Diabetes and its Complications, Vol. 28, No. 3
  - Anandamide Attenuates Th-17 Cell-Mediated Delayed-Type Hypersensitivity Response by Triggering IL-10 Production and Consequent microRNA Induction
    3 April 2014 | PLoS ONE, Vol. 9, No. 4
  - Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype
    28 July 2013 | Journal of Neuroimmune Pharmacology, Vol. 8, No. 5
  - Curcumin modulates cannabinoid receptors in liver fibrosis in vivo and inhibits extracellular matrix expression in hepatic stellate cells by suppressing cannabinoid receptor type-1 in vitro
    European Journal of Pharmacology, Vol. 721, No. 1-3
  - Immunosuppressive and anti-inflammatory effects of N-acyl dopamines on Con A-stimulated splenocytes of BALB/c mouse
    10 September 2013 | European Journal of Lipid Science and Technology, Vol. 115, No. 11
  - Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders
    13 April 2013 | Journal of Autism and Developmental Disorders, Vol. 43, No. 11
  - Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors
    29 July 2013 | Allergy, Vol. 68, No. 8
  - The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action
    27 May 2013 | British Journal of Pharmacology, Vol. 169, No. 4
  - Interleukin-17 in post-stroke neurodegeneration
    Neuroscience & Biobehavioral Reviews, Vol. 37, No. 3
  - The role of CB1 in immune modulation by cannabinoids
    Pharmacology & Therapeutics, Vol. 137, No. 3
  - Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury
    Cellular Signalling, Vol. 25, No. 2
  - The role of endocannabinoids in pain modulation
    2 January 2013 | Fundamental & Clinical Pharmacology, Vol. 27, No. 1
  - Endocannabinoid-Mediated Synaptic Plasticity
    8 July 2013
  - RNAi screen in apoptotic cancer cell-stimulated human macrophages reveals co-regulation of IL-6/IL-10 expression
    Immunobiology, Vol. 218, No. 1
  - The molecular connections between the cannabinoid system and endometriosis
    24 August 2012 | Molecular Human Reproduction, Vol. 18, No. 12
  - Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation
    17 July 2012 | Glia, Vol. 60, No. 11
  - Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats
    12 May 2012 | Inflammation Research, Vol. 61, No. 9
  - Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB 1 Receptor
    17 May 2012 | Journal of Medicinal Chemistry, Vol. 55, No. 11
  - ALSUntangled No. 16: Cannabis
    28 May 2012 | Amyotrophic Lateral Sclerosis, Vol. 13, No. 4
  - “Redundancy” of Endocannabinoid Inactivation: New Challenges and Opportunities for Pain Control
    15 March 2012 | ACS Chemical Neuroscience, Vol. 3, No. 5
  - Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch
    Biochemical Pharmacology, Vol. 83, No. 10
  - CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity
    29 March 2011 | Journal of Psychopharmacology, Vol. 26, No. 1
  - Perinatal Exposure to Δ 9 -Tetrahydrocannabinol Triggers Profound Defects in T Cell Differentiation and Function in Fetal and Postnatal Stages of Life, Including Decreased Responsiveness to HIV Antigens
    10 August 2011 | Journal of Pharmacology and Experimental Therapeutics, Vol. 339, No. 2
  - Targeting Cannabinoid Receptors as a Novel Approach in the Treatment of Graft-versus-Host Disease: Evidence from an Experimental Murine Model
    14 June 2011 | Journal of Pharmacology and Experimental Therapeutics, Vol. 338, No. 3
  - Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation
    Journal of Inflammation, Vol. 8, No. 1
  - Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials
    3 May 2010 | American Journal of Hospice and Palliative Medicine®, Vol. 27, No. 5
Vol. 1, No. 7

Metrics
Downloaded 232 times

History

Published online 21 October 2009

Published in print October 2009

Information
© Future Science Ltd
Financial & competing interests disclosure
This work was supported in part by NIH grants R01AI053703, R01ES09098, R01AI058300, R01DA016545, R01HL058641 and P01AT003961. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Loading ...